[Calmodulin antagonist inhibits torsade de pointes induced by d-sotalol in an isolated rabbit heart model]
Related Experiment Video
Updated: Aug 17, 2026

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates
Published on: October 18, 2018
Jun Pu1, Cun-tai Zhang, Rong Bai
1Department of Cardiology, Tongji Hospital, Affiliated of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Objective:
To evaluate the effects of W-7, a calmodulin inhibitor, on transmural dispersion of repolarization (TDR), early after depolarization (EAD) and torsade de pointes (TdP) induction after administration of d-sotalol in isolated rabbit heart.
Methods:
TdP was induced by d-sotalol (30 micromol/L), bradycardia, and hypokalemic (1.5 mmol/L)/hypomagnesaemic (0.35 mmol/L) solution in isolated female rabbit hearts. Thirty six rabbit hearts were divided into 4 groups (n = 9 each): d-sotalol alone, d-sotalol + W-7 (20 micromol/L), d-sotalol + W-7 (50 micromol/L), and d-sotalol + W-7 (100 micromol/L). Monophasic action potentials (MAPs) of the left ventricular epimyocardium (Epi), midmyocardium (M), and endomyocardium (Endo) were recorded simultaneously with ECG. The incidence of EAD and TdP were observed as well.
Results:
Treatment with d-sotalol alone prolonged ventricular MAP duration and QT interval, increased TDR, and evoked high incidence of EAD (9/9) and spontaneous TdP (7/9) in hypokalemic/hypomagnesaemic solution in female rabbit heart. W-7 concentration-dependently decreased incidence of TdP (4/9 in 20 micromol/L; 2/9 in 50 micromol/L; 1/9 in 100 micromol/L). This effect of W-7 coincided with the decreased incidence of EAD (5/9 in 20 micromol/L; 4/9 in 50 micromol/L; 1/9 in 100 micromol/L). However, the d-sotalol-induced prolongation of QT interval and TDR was not significantly altered by W-7 at the three concentration used.
Conclusions:
In isolated female rabbit hearts, calmodulin antagonist W-7 suppresses d-sotalol-induced TdP without altering TDR but does suppress EAD. The effects observed with W-7 also suggest a possible important role for calmodulin-activated enzymes in the induction of TdP.
Insights
Calmodulin inhibitor W-7 reduced torsade de pointes (TdP) and early afterdepolarizations (EAD) in d-sotalol-treated rabbit hearts. W-7 suppressed TdP and EAD without affecting transmural dispersion of repolarization (TDR).
Area of Science:
- Cardiovascular Pharmacology
- Electrophysiology
- Molecular Cardiology
Context:
- D-sotalol can induce life-threatening arrhythmias like torsade de pointes (TdP).
- Calmodulin plays a role in regulating cardiac ion channels and contractility.
- Understanding modulators of TdP is crucial for patient safety.
Purpose:
- To investigate the antiarrhythmic effects of W-7, a calmodulin inhibitor, on d-sotalol-induced TdP.
- To assess W-7's impact on transmural dispersion of repolarization (TDR) and early afterdepolarizations (EAD).
Summary:
- W-7 concentration-dependently reduced the incidence of TdP and EAD in isolated rabbit hearts treated with d-sotalol.
- W-7 did not significantly alter the d-sotalol-induced prolongation of QT interval or TDR.
- These findings suggest calmodulin-activated enzymes are involved in TdP induction.
Impact:
- Provides evidence for W-7 as a potential therapeutic agent against TdP.
- Highlights the role of calmodulin in drug-induced cardiac arrhythmias.
- Offers insights into the mechanisms underlying TdP and EAD.
More Related Videos
Related Concept Videos
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Heart Failure Drugs: Inotropic Agents
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Antihypertensive Drugs: Action of Calcium Channel Blockers

